Redefining obesity based not only on body mass index (BMI) but on whether excess body fat is causing measurable health ...

The Lancet obesity framework aims to improve risk assessment but risks delaying treatment and deepening health inequities, according to recent evaluations.

Revised diagnostic framework may limit access to early treatment, widen healthcare dispari ...

The Endocrine Society has concerns of possible delays in care and other problematic areas of The Lancet Commission’s proposed new obesity framework; a Commission author cites ‘conceptual confusions.’ ...

Redefining obesity based not only on body mass index (BMI) but on whether excess body fat is causing measurable health problems may complicate diagnosis and delay treatment, according to an Endocrine ...

Redefining obesity based not only on body mass index (BMI) but on whether excess body fat is causing measurable health ...

Learn how doctors categorize obesity into classes using BMI, as well as related health risks and treatments based on the ...

Medications like GLP-1 agonists, as well as minimally invasive bariatric surgeries, offer lasting results with few complications. At the same time, healthy eating and regular physical activity remain ...

News and commentary from the endocrinology world ...

The Government of India has tightened regulation of GLP-1 drugs used for diabetes and weight loss, restricting prescriptions ...

The FDA approved a once-daily oral GLP-1 receptor agonist for adults with obesity or overweight with weight-related ...

FDA approval of Lilly oral obesity drug ignites pill race against Wegovy Lillys once-daily Foundayo wins rapid FDA nod, ...